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In order to assess the effect of Pegfilgrastim on the duration of neutropenia and clinical outcome
of patients after autologous peripheral blood stem cell (PBSC) transplantation, we compared 20
consecutive patients with lymphoma or multiple myeloma receiving a single 6-mg dose of Peg-
filgrastim on day 1 posttransplant to an historical control group of 60 patients receiving daily
Filgrastim 5 mg/kg starting on day 1 posttransplant. The duration of neutropenia was similar in
the Pegfilgrastim group compared with the control group. There were no differences in time to
neutrophil, erythroid, or platelet engraftment nor in the incidence of fever and infections. The
duration of antibiotic therapy, transfusion support, and time to hospital discharge were similar
in the two groups. However, after initial hematopoietic reconstitution, we observed significantly
higher values of lymphocytes (e.g., 16606 1000 versus 9706 460 on day 80, p[ 0.0002), neu-
trophils (e.g., 3880 6 2030 versus 2420 6 1500 on day 25, p [ 0.0004), reticulocytes (e.g.,
148,160 6 90,590 versus 87,140 6 65,920 on day 25, p ! 0.0001), and platelets (e.g., 210,700
6 116,090 versus 150,240 6 58,230 on day 55, p[ 0.0052) up to day 100 in the Pegfilgrastim
group compared with the Filgrastim group. These observations had no impact on clinical out-
come of the patients after day 30 due to the low incidence of infectious events after engraftment
in autologous PBSC transplantation.We conclude that the effect of Pegfilgrastim administrated
on day 1 posttransplant is comparable to that of daily Filgrastim on initial hematopoietic recon-
stitution. The possibly superior effect of Pegfilgrastim on cell counts we observed after initial
engraftment should be further tested in a prospective randomized trial.  2006 International
Society for Experimental Hematology. Published by Elsevier Inc.High-dose chemotherapy followed by autologous hemato-
poietic stem cell transplantation (HCT) is a widely accepted
treatment modality for several selected hematologic malig-
nancies. Low neutrophil counts in the early posttransplant
period facilitate the occurrence of severe infectious compli-
cations and have a significant impact on overall morbidity
and mortality after autologous HCT [1–4]. Various reports
have shown that recombinant hematopoietic growth factors
such as granulocyte colony-stimulating factor (G-CSF)
[5–12] or granulocyte-macrophate colony-stimulating
factor (GM-CSF) [13] significantly reduce the time to
neutrophil recovery following autologous peripheral blood
stem cell (PBSC) transplantation. Moreover, these previous
studies have shown that the use of these myeloid growth
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i: 10.1016/j.exphem.2005.11.013factors significantly decreases number of bacterial infec-
tions, number of days on antibiotics, and duration of initial
hospitalization.
Research investigations have shown that their modifica-
tion by chemical addition of poly(ethylene glycol) can alter
the pharmacokinetic and pharmacodynamic properties of
various proteins to significantly increase the time the mod-
ified proteins remain effective in the circulation [14]. Moli-
neux et al. have developed a form of Filgrastim modified by
the addition of a linear pegylated (PEG) molecule of 20 kD
covalently bound to the N-terminus showing a sustained du-
ration of action in vivo [15]. Clinical studies have demon-
strated that Pegfilgrastim was as safe and effective as
daily Filgrastim in several settings [16–20]. Pegfilgrastim
administered once per cycle after chemotherapy for non–
small cell lung cancer (NSCLC) [21], breast cancer
[16,17], or lymphoma [18,20] provided neutrophil support
and presented a safety profile comparable to that of daily
Filgrastim. Successful transplantation of PBSC mobilizedor Experimental Hematology. Published by Elsevier Inc.
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been reported in patients with multiple myeloma [19].
The ability of a single injection of Pegfilgrastim to improve
neutrophil recovery following bone marrow transplantation
has been illustrated in rhesus macaques [22]. Recently,
a few articles [23,24] and abstracts [25,26] compared the
administration of a single 6-mg dose of Pegfilgrastim
with daily Filgrastim after autologous PBSC transplanta-
tion. However, in these studies, the two treatments were
started on differing days posttransplant (i.e., dayD3 versus
dayD5 [26], dayD2 versus day D5 [25], dayD1 versus
daysD1 orD4 [23], and dayD5 versus dayD7 [24]). In
addition, the evolution of hematologic parameters after ini-
tial hematopoietic recovery is not known. We present here
our experience with the use of Pegfilgrastim compared with
Filgrastim, both started on day 1 posttransplant, with 100-
day follow-up after autologous PBSC transplantation.
Patients and methods
Patients
Between May 2004 and November 2004, 20 consecutive autolo-
gous stem cell transplantation recipients with lymphoid malignan-
cies were treated with Pegfilgrastim after transplantation. They
were compared to a historical control group of 60 patients selected
in our database of patients receiving an autologous PBSC trans-
plant and daily Filgrastim starting on day 1 in the preceding 3
years. This control group was matched 3:1 with the study group
on the basis of age, sex, diagnosis, disease status at time of trans-
plant, transplantation number, and starting day of posttransplant
G-CSF. Patient characteristics are given in Table 1. All patients
gave written informed consent to analysis of their clinical data
and this process was approved by the Ethics Committee of the
University of Lie`ge.
PBSC collection and transplantation
Multiple myeloma patients were mobilized with cyclophospha-
mide 4.5 g/m2 and G-CSF 5 mg/kg/d, and lymphoma patients
with cyclophosphamide 4.5 g/m2, VP16 1.5 g/m2, and G-CSF.
PBSC were harvested in all patients by leukapheresis as previ-
ously described [27,28] and stored without further manipulation
in liquid nitrogen in 7.5% dimethylsulfoxide. Conditioning regi-
mens consisted of cyclophosphamide (120 mg/kg) D total body
irradiation (12 Gy) for low-grade lymphoma (n 5 15), BCNU,
Etoposide, Ara-C, Melphalan (BEAM) for high-grade lymphoma
or Hodgkin’s disease (n 5 15), and Melphalan (200 mg/m2) for
multiple myeloma (n 5 50). On the day of transplantation, cells
were rapidly thawed and infused through a central catheter.
Growth factors
In the study group, Pegfilgrastim (Neulasta, Amgen, Thousand
Oaks, CA, USA) was administered at a single intravenous dose
of 6 mg on day 1 posttransplant. In the historical control group,
Filgrastim (Neupogen, Amgen, Thousand Oaks, CA, USA) was
administered at a dose of 5 mg/kg/d from day 1 posttransplant until
the absolute neutrophil count (ANC) was $1 3 109/L for 3 days
or $10 3 109/L for 1 day, whichever came first. In both groups,additional doses of Filgrastim were given when the ANC fell
below 1 3 109/L at any time before day 100 posttransplant.
Clinical management
Until engraftment, patients were kept in laminar air flow rooms
and received chlorhexidine mouthwashes. Patients also received
acyclovir (250 mg/m2 b.i.d. intravenously and then orally as
soon as feasible until day 40), oral antifungal prophylaxis with ei-
ther 400 mg itraconazole or 400 mg fluconazole until day 40, and
aerosolized pentamidine until day 120. All patients were managed
with a totally implanted Port-A-Cath catheter (Braun, Melsungen,
Germany) that remained in place at least until 1 year posttrans-
plant. In case of fever above 38.3C once or above 38C on three
consecutive measurements, empirical antibiotic therapy was
started with a combination of cefepim D amikacin [29]. Patients
were weekly screened for cytomegalovirus (CMV) by polymerase
chain reaction (PCR). Preemptive therapy with ganciclovir (10
mg/kg intravenously thrice weekly) was initiated after a positive
PCR and discontinued after two consecutive negative results.
We used the definitions of the Infectious Diseases Working Party
of the European Bone Marrow Transplant Group (EBMT) for
diagnosis of bacteremia, fungemia, varicella-zoster virus infec-
tions, CMV infection, or disease [30]. Fever of unknown origin
was defined as fever alone without clinical sign or bacteriologic
documentation.
Complete blood counts were determined in an Advia cell
counter (Bayer, Tarrytown, NJ, USA). Red blood cell (RBC)
and platelet transfusions were given when the hemoglobin or
platelet count were below 8 g/dL or 15 3 109/L, respectively.
Statistical analyses
Unpaired and paired Student’s t-tests as well as two-way analysis
of variance were used to compare biologic parameters in the two
groups. Welsh’s correction was used in case of unequal variance.
Table 1. Patient characteristics
Filgrastim Pegfilgrastim p value
Number of patients 60 20
Age (Mean 6 SD) 56 6 9 54 6 10
Sex
Males 41 (68%) 13 (65%) 0.7820
Females 19 (32%) 7 (35%)
Disease
NHL D HD 20 (30%) 10 (50%) 0.1824
MM 40 (70%) 10 (50%)
Disease status
CR 17 (28%) 9 (45%) 0.1680
Not in CR 43 (72%) 11 (55%)
Prior autologous HCT
Yes 19 (32%) 6 (30%) 0.8890
No 41 (68%) 14 (70%)
CMV status
CMVD 27 (45%) 16 (80%) 0.0065
CMV2 33 (55%) 4 (20%)
Graft composition (Mean 6 SD)
CD34D cells (3106/kg) 10.03 6 6.25 7.16 6 3.82 0.0575
CFU-GM (3104/kg) 281.21 6 258.70 232.12 6 27.11 0.7968
NHL, Non-Hodgkin’s lymphoma; HD, Hodgkin’s disease; MM, multiple
myeloma; CR, complete remission.
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Mann-Whitney U-tests. Times to hematopoietic recovery were
studied by life table analyses and Wilcoxon rank tests were used
for comparisons between groups. Clinical outcome parameters
were analyzed by Chi-square tests. Statistical analyses were car-




There was no significant difference in initial neutrophil en-
graftment between the two groups. Time to reach an ANC
of 0.5 (Fig. 1) or 13 109/L or the number of days with neu-
tropenia (Table 2) were similar in the two groups. Similarly,
no difference was seen between the two groups for time to
unsupported platelet count $ 20 or 100 3 109/L or the
number of platelet transfusions (Table 2). There was also
no significant difference in time to 1% reticulocytes or
the number of red cell units transfused (Table 2).
After initial hematopoietic recovery, several differences
between the groups became apparent. When significant,
these differences always consisted in the Pegfilgrastim
group showing higher counts compared with the Filgrastim
group. The neutrophil count (day 25: 3880 6 2030 versus
2420 6 1500; p 5 0.0004) remained significantly higher
in the study group between days 14 and 30 (Fig. 2), as
did the lymphocyte count (day 80: 1660 6 1000 versus
970 6 460; p 5 0.0002) between days 56 and 90
(Fig. 2), the monocyte count between days 21 and 24, retic-
ulocytes (day 24: 148,160 6 90,590 versus 87,140 6
65,920; p ! 0.0001) between days 17 and 42 (Fig. 2),
and the platelet count (day 56: 210,700 6 116,090 versus
150,240 6 58,230; p 5 0.0052) between days 35 and day
90 (Fig. 2), respectively.
After the initial hematopoietic recovery and up to day
100, a total of three supplementary doses of Filgrastim









































Figure 1. Kaplan-Meier plot of time to 0.5 3 109/L neutrophils in the
Pegfilgrastim group compared with the Filgrastim group.had to be administered to three patients in the Pegfilgrastim
group (0.15 6 0.37 per patient) and a total number of 24
doses to 20 patients in the control group (0.40 6 0.94 per
patient; not significant).
Infections
Clinically relevant infections occurring within 100 days
posttransplant in the two groups are summarized in Table 3.
There was no difference between the two groups for the
overall incidence of infection, nor for specific rates of
bacteremia, other bacterial infections, fungal infections,
or zoster infections. The number of patients with CMV in-
fection was higher in the study group, but this was only due
to the larger proportion of CMV seropositive patients in this
group compared to the control group (p 50.0065). Finally,
there was no difference for the number of days with fever,
days on antibiotics, days on amphotericin B, or duration of
hospitalization. The cost of G-CSF until engraftment was
12376 277V/patient with Filgrastim versus 1207V/patient
with Pegfilgrastim (p 5 0.6210).
Discussion
High-dose chemotherapy followed by autologous HCT
is widely used in the treatment of patients with mul-
tiple myeloma and lymphoma. Severe and life-threatening
infections complicating the profound and prolonged myelo-
suppression inevitably induced by high-dose chemotherapy
remain a major factor of morbidity and mortality in patients
undergoing autologous HCT [3,4]. The use of G-CSF after
Table 2. Hematological recovery after transplantation
Filgrastim Pegfilgrastim p value
Days to 0.5 3 109/L neutrophils
(median)
9 8 0.2281
Days to 1.0 3 l09/L neutrophils
(median)
9 9 0.1620
Days to 1% reticulocytes
(median)
15 13 0.1416
Days to last RBC transfusion
(median)
8 7 0.6285
Days to 20 3 109/L platelets
(median)
9 9 0.6510
Days to 100 3 109/L platelets
(median)
31 20 0.4206
Days to last platelet transfusion
(median)
7 6 0.5428
Number of G-CSF injections* 10.7 6 1.7 1
Number of additional G-CSF
injectionsy
0.4 6 0.9 0.2 6 0.4 0.2513
Number of red blood cell
transfusions
0.9 6 1.6 1.1 6 1.6 0.5542
Number of platelet transfusions 1.0 6 1.7 1.2 6 1.8 0.7142
*Number of injections until full neutrophil engraftment (see Methods).
yNumber of injections for secondary neutropenia after initial neutrophil
engraftment.
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Figure 2. Neutrophil (A), lymphocyte (B), platelet (C), and reticulocyte (D) counts after transplantation in the Pegfilgrastim group compared with the
Filgrastim group. *p ! 0.05; **p ! 0.01; ***p ! 0.001.autologous bone marrow transplantation has been shown to
shorten the duration of severe neutropenia and thereby to
reduce the risk of infections [1,2,31]. Compared to trans-
plantation of bone marrow, autologous infusion of PBSC
is associated with a reduced period of neutropenia, fewer
infectious complications, and shorter duration of hospitali-
zation [32]. Several authors have reported that G-CSF can
reduce the duration of early severe neutropenia by a few
days to 1 week after high-dose chemotherapy and autolo-
gous transplantation of PBSC, which may then lead to a de-
creased incidence of infectious complications, reduced use
of antibiotics, and shorter duration of hospitalization [5–
12]. However, the duration of G-CSF action is limited by
its removal from the body by two mechanisms. The first
mechanism is thought to be mediated by G-CSF receptors
(receptor-mediated clearance), predominantly on neutro-
phils [33–35]. The second process is likely the result of re-
nal clearance [34,35]. A new form of Filgrastim, modifiedby the addition of PEG, has been produced. A single dose
of Pegfilgrastim results in sustained drug concentration in
serum [17,20,22] thanks to the poly(ethylene glycol) mod-
ification of Filgrastim that causes decreased renal clearance
of the protein [36].
Molineux et al. [15] demonstrated that a single injection
of Pegfilgrastim produced significantly elevated neutrophil
counts for 5 days in hematologically normal mice or for
9 to 10 days in normal human volunteers. In neutropenic
mice, its effect was prolonged for at least 9 days and pro-
duced a significant reduction in the duration of chemother-
apy-induced neutropenia. Johnston et al. [21] demonstrated
that a single injection of Pegfilgrastim in NSCLC patients
receiving chemotherapy was as safe and effective on
ANC and CD34D cell mobilization as daily Filgrastim.
This efficacy and safety profile was confirmed by Holmes
et al. [16,17] in woman with breast cancer receiving chemo-
therapy. Vose et al. [18] illustrated similar effects of
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patients undergoing salvage chemotherapy.
Farese et al. [22] examined the ability of a single injection
of Pegfilgrastim to significantly improve neutrophil recovery
following bone marrow transplantation in rhesus macaques
and showed that the stimulation of granulopoiesis was equiv-
alent to that observed with Filgrastim. A few studies have
been conducted in patients undergoing PBSC transplanta-
tion. Soussain et al. [37] showed in 15 patients that a fixed
6-mg dose of Pegfilgrastim on dayD3was safe and effective.
Musso et al. [25] observed that neutrophil engraftment, dura-
tion of hospitalization, and duration of intravenous antibi-
otics were similar in five patients receiving 6 mg
Pegfilgrastim on day D2 and five other patients treated
with daily Filgrastim from dayD5. Musto et al. [26] demon-
strated that 6 mg Pegfilgrastim on dayD3 and daily Filgras-
tim fromdayD5 (11 patients in both groups) had comparable
safety and efficacy profiles. Neutrophil engraftment occurred
2 days earlier with Pegfilgrastim, corresponding to the delay
in initiating the two treatments. Jagasia et al. [23] confirmed
that a single 6-mg dose of Pegfilgrastim on dayD1 appeared
safe and accelerated neutrophil engraftment comparable to
daily Filgrastim started on day D1 or D4 (38 patients in
each group). However, these authors did not compare the
clinical outcome of patients receiving Pegfilgrastim with
that of patients receiving Filgrastim. Staber et al. [24] showed
that a single 6-mg dose of Pegfilgrastim on dayD5 reduced
the duration of grade 4 neutropenia, the duration of febrile
Table 3. Infectious complications after transplantation
Filgrastim Pegfilgrastim p value
Duration of hospitalization
after transplant
15.4 6 5.8 14.5 6 3.3 0.4991
Days with fever 2.3 6 2.4 2.7 6 2.3 0.5140
Days on IV antibiotics 8.4 6 5.9 8.7 6 5.9 0.8495
Days on IV amphotericin B 1.7 6 5.1 2.6 6 5.6 0.5068
Number of patients with
possible infection
(Fever of unknown origin)
18 (30%) 8 (40%) 0.3857
Number of patients
with bacteremia
11 (18%) 7 (35%) 0.1221
Number of patients
with other bacterial infection
24 (40%) 7 (35%) 0.4082
Number of patients
with fungal infection
1 (2%) 1 (5%) 0.4082
Number of patients
with CMV infection




9 (33%) 9 (56%) 0.1409
Number of patients
with CMV disease




1 (3%) 0 (0%) 0.4360
Number of patients with
Zoster infection
4 (6%) 0 (0%) 0.2360neutropenia, and the number of days of fever compared
with daily Filgrastim started on day D7 (30 patients in
each group).
However, in all these studies the two treatment modalities
were started on differing days posttransplant (i.e., day D3
versus day D5 [26], day D2 versus dayD5 [25], dayD1
versus days D1 or D4 [23], and day D5 versus day D7
[24]). Our study compared 20 consecutive patients receiving
Pegfilgrastim at a single dose of 6 mg on dayD1 after trans-
plantation with a historical control group of 60 patients re-
ceiving Filgrastim at a daily dose of 5 mg/kg also starting
on dayD1 posttransplant. The kinetics of early hematopoi-
etic recovery was quite similar in the two groups, including
neutrophil, erythroid, and platelet reconstitution. There was
no more use of additional G-CSF doses after initial hemato-
poietic recovery in the Pegfilgrastim group compared with
the Filgrastim group. No difference was observed between
the two groups for infectious events. Although we observed
significantly more CMV infections in the group of patients
receiving Pegfilgrastim, this was only due to a higher pro-
portion of CMV-seropositive patients in this group. Our
study had a similar design to the Jagasia study [23], although
in that study, an unknown proportion of the patients started
Filgrastim on day D4. We achieved similar results for
neutrophil recovery but other comparative data were not
available in the Jagasia study [23].
Previous trials comparing Pegfilgrastim with Filgrastim
outside of the transplant setting studied hematopoietic re-
covery after standard chemotherapy given in repeated cy-
cles at intervals shorter than 4 weeks. Studies conducted in
autologous transplant recipients only evaluated the impact
of Pegfilgrastim on the primary hematopoietic recovery after
autologous PBSC transplantation. Therefore, the evolution
of blood cell counts could never be observed beyond day
30 postchemotherapy. In our study, a longer follow-up of
100 days posttransplant could be obtained. This may explain
why we are the first to report a significant difference in the
evolution of blood cell parameters in favor of the patients re-
ceiving Pegfilgrastim compared with those receiving Fil-
grastim. Indeed, we observed that neutrophil, lymphocyte,
monocyte, reticulocyte, and platelet counts, although quite
similar initially, were significantly higher in the group of pa-
tients receiving Pegfilgrastim during various periods of time
after initial hematopoietic recovery. This took place despite
a trend toward fewer CD34D cells transplanted in the Pegfil-
grastim group. One could speculate that this would suggest
broader effects of Pegfilgrastim on progenitor cell recovery
but this remains to be demonstrated. However, this discrep-
ancy did not translate into differences in clinical outcome,
probably because most infections occurred in the early pe-
riod of neutropenia. This apparently superior effect on cell
counts of Pegfilgrastim over Filgrastim should be confirmed
in prospective randomized trials that should also address
the question of cost-effectiveness of Pegfilgrastim in this
setting. Musso et al. [25] also suggested that Pegfilgrastim
387G. Vanstraelen et al./ Experimental Hematology 34 (2006) 382–388administration could result in significant time savings for
staff by reducing the number of drug administrations. With
the convenience of a single-dose administration, Pegfilgras-
tim could become the future standard of care after autolo-
gous PBSC transplantation if its efficacy and cost can be
proven to be at least equivalent to Filgrastim.
In our study, the cost of G-CSF was quite similar with
Pegfilgrastim and Filgrastim. However, some studies have
shown that postponing the initiation ofG-CSFadministration
until day 5 or 6 posttransplant would not produce significant
delays in neutrophil recovery [12,38,39]. Moreover, early
discontinuation of G-CSF as soon as white blood cells reach
a value of 1000/mL or neutrophils reach a value of 500/mL for
2 days after autologous hematopoietic stem cell transplanta-
tion is now being considered by some [40]. This would re-
duce the cost of Filgrastim administration and render
Pegfilgrastim more expensive, unless a lower dose could do
the job. However, in clinical practice, translating later initia-
tion of Filgrastim treatment into lesser use of G-CSF is not
straightforward. In the studies that compared daily Filgrastim
with single-dose Pegfilgrastim, the number of Filgrastim
doses ranged from seven when Filgrastim was started on
dayD7 [24] to 12 [26] or approximately 10 [25] when Fil-
grastim was started on day D5, approximately 8 to 11
when Filgrastim was started on day D1 or D4 [23], and
10.7 in our study in which Filgrastim was started on day
D1. Therefore, initiating Filgrastim administration on day
D5 does not automatically lead to fewer doses used com-
pared with initiation on day D1. Prospective randomized
studies that compare Pegfilgrastim with Filgrastim, ideally
started on the same day, are warranted.
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